NDA 213189 · Almirall
Klisyri
Tirbanibulin · Topical · Microtubule Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jun 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 14, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
17
3 Phase 3, 3 recruiting
FAERS reports
249
49 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 24, 2026.
KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp. KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp. ( 1 )
Mechanism: Tirbanibulin is a microtubule inhibitor. The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 7, 2024 Supplement 5 · Efficacy LetterLabel
- Dec 14, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- KLISYRI · TIRBANIBULIN 1% · OINTMENT, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tirbanibulin" as an intervention, any sponsor and status, largest first.
- A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpPivotal-lookingActive, not recruiting
Almirall, S.A.Industry
NCT05387525 · 447 participants · Start Oct 24, 2022 · Primary completion Jul 2027
Drug: Tirbanibulin (Klisyri®) 10 mg/g ointment; Diclofenac Sodium 3% Gel · For: Keratosis, Actinic
Sites: Lille, France; Marseille, France; Nice, France · 49 sites in all
Almirall, S.A.Industry
NCT05741294 · 334 participants · Start Jan 20, 2023 · Primary completion Jan 19, 2024
Drug: Tirbanibulin 2.5 mg ointment · For: Actinic Keratosis
Sites: Cagliari, Italy; Catania, Italy; Naples, Italy · 37 sites in all
- A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic KeratosisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT06135415 · 280 participants · Start Dec 21, 2023 · Primary completion Apr 30, 2025
Drug: Tirbanibulin · For: Keratosis, Actinic
Sites: Augsburg, Germany; Bad Bentheim, Germany; Bochum, Germany · 35 sites in all
- A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic KeratosisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT05279131 · 105 participants · Start Jun 28, 2022 · Primary completion Dec 28, 2022
Drug: Tirbanibulin ointment 1% · For: Keratosis, Actinic
Sites: Hot Springs, Arkansas; Encinitas, California; Sweetwater, Florida · 7 sites in all
- Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin OintmentRecruiting
Bruce Robinson, MDAcademic, hospital or other
NCT07010692 · 100 participants (planned) · Start May 16, 2025 · Primary completion May 2030
Drug: Tirbanibulin ointment 1% · For: Keratinocyte Carcinoma; Basal Cell Carcinomas; Squamous Cell Carcinoma and 1 more
Sites: New York, New York
Hanmi Pharmaceutical Company LimitedIndustry
NCT01764087 · 60 participants (planned) · Start Dec 2012 · Primary completion Dec 2015
Drug: KX2-391 and Paclitaxel · For: Unspecified Adult Solid Tumor, Protocol Specific; Gastric Cancer; Breast Cancer
Sites: Seongnam-si, South Korea; Seoul, South Korea
- Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and ForeheadPivotal-lookingNot yet recruiting
University Hospital, LilleAcademic, hospital or other
NCT07273656 · 59 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: Cryotherapy + Tirbanibulin · For: Keratosis; Actinic Keratoses
Athenex, Inc.Industry
NCT00658970 · 50 participants (planned) · Start Nov 2007 · Primary completion Mar 2010
Drug: KX2-391 · For: Solid Tumors; Lymphoma
Sites: Philadelphia, Pennsylvania; Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective48
- application site erythema36
- erythema25
- drug intolerance20
- adverse drug reaction17
- application site exfoliation17
- application site vesicles16
- off label use15
- application site pain13
- pruritus12
- application site dryness10
- application site pruritus10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 7 |
| 2022 | 65 |
| 2023 | 27 |
| 2024 | 79 |
| 2025 | 39 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Klisyri (Tirbanibulin)
2024 spending
$3.4M
Beneficiaries
2,207
2,868 claims
Per beneficiary
$1,560
$224.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,153,842 |
| 2022 | $2,124,928 |
| 2023 | $3,001,296 |
| 2024 | $3,443,218 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Blauvelt A, Kempers S, Lain E, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Systematic review of randomized controlled trials of topicals for actinic keratosis field therapy.
Patel P, Wang J, Bitterman D, et al. · Arch Dermatol Res 2024 · Systematic Review
- Focused update: Guidelines of care for the management of actinic keratosis.
Eisen DB, Dellavalle RP, Frazer-Green L, et al. · J Am Acad Dermatol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Randomized comparative study of 5-Fluorouracil 4%, tirbanibulin, and photodynamic therapy for relapsing actinic keratoses.
Venturi F, Magnaterra E, Gualandi A, et al. · Photodiagnosis Photodyn Ther 2026 · Randomized Controlled Trial, Comparative Study
- Efficacy and safety of sequential treatment with cryotherapy followed by 1% topical tirbanibulin for actinic keratoses in organ transplant recipients: A randomized clinical trial.
Morelló-Vicente A, Oteiza-Rius I, Gómez-González EM, et al. · J Am Acad Dermatol 2025 · Randomized Controlled Trial, Comparative Study
- A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.
Kasner MT, Halloran MB, Pan J, et al. · Invest New Drugs 2022 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.